Diabetes Associated Ophthalmic Treatment Market Size Report, 2024-2033
The global diabetes-associated ophthalmic treatment market was estimated at USD 27.30 billion in 2023, is expected to surpass around USD 52.22 billion by 2033, and is poised to grow at a compound annual growth rate (CAGR) of 6.7% during the forecast period of 2024–2033.
Key Takeaways:
Diabetes-Associated Ophthalmic Treatment Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 27.30 Billion |
| Market Size by 2033 | USD 52.22 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 6.7% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Type, Application; End-Use; Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Alcon; Johnson & Johnson Services, Inc.; Bausch Health; Allergan; Bayer AG; Santen Pharmaceutical Co. Ltd.; Novartis AG; Pfizer, Inc.; Genentech, Inc.; Carl Zeiss Meditec; Lumenis; Ellex Medical Lasers Ltd.; IRIDEX Corporation; Topcon Corporation; Abbott Medical Optics; Quantel. |
The factors influencing market growth include the increasing prevalence of type II diabetes, the growing geriatric population, rising incidences of vision loss due to excess diabetic conditions, increasing awareness regarding ophthalmic disorders, and inclination towards early diagnosis. Furthermore, advancements in technology have resulted in the invention of new and safer products to treat diabetes-associated ophthalmic diseases. However, the lack of skilled ophthalmologists and the longer duration of drug approvals are expected to hinder market growth.
An increase in the incidence of diabetes due to aging, obesity, and an unhealthy lifestyle is one of the factors contributing to the growth of the market for diabetes-associated ophthalmic. Obesity is a major factor causing diabetes leading to the increased incidences of diabetes-associated ophthalmic disorders. In 2017, the global incidence of diabetes was reported for around 22.9 million, the prevalence accounted for around 476.0 million, around 1.37 million deaths were reported due to diabetes, and disability-adjusted life-years (DALYs) associated with diabetes were reported to around 1.37 million. According to the WHO, in 2017, over 1.9 billion adults were overweight, of which, around 650 million people were classified as obese. Risk factors, such as obesity and overweight, are leading to an increase in the incidence of type II diabetes. Therefore, risk factors such as smoking, overweight, obesity, and high cholesterol are expected to boost the prevalence of type II diabetes.
Diabetes and ophthalmic conditions related to the COVID-19 recovery are expected to play an important market driver. Patients recovered from COVID-19 are showing long-term progressions in diabetic as well as ophthalmic conditions. Identification of new coronavirus strains is expected to increase the duration of the ongoing pandemic due to the limitations of the existing vaccines.
The increasing number of initiatives being undertaken by governments and nonprofit organizations to increase diabetes associated ophthalmic disease awareness is expected to boost the adoption of devices used for the treatment. Furthermore, WHO and IDF are working together to prevent and control diabetes and ensure a good quality of life for people worldwide by providing accessible treatment facilities. For instance, the WHO Diabetes Program is aimed at preventing type 2 diabetes, reducing complications, and improving quality of life. NGOs and governments are creating norms and standards, raising awareness about diabetes prevention, and promoting surveillance to strengthen the prevention and control of diabetes.
Type Insights
The drugs segment dominated the market for diabetes-associated ophthalmics and accounted for the largest revenue share of 57.6% in 2023. The drug segment comprises anti-glaucoma drugs, anti-inflammatory drugs, anti-VEGF drugs, anti-allergy drugs, and others. The drug segment is propelling due to factors such as the presence of major key players operating in the global market, a high adoption rate, increased clinical trials to develop innovative drugs. The device segment is growing at a rapid pace, accounting for a CAGR of 6.4% during the forecast period. The devices segment comprises refractive error surgical devices, glaucoma surgical devices, cataract surgical devices, vitreoretinal surgical devices, diagnostic devices, and visual aid devices.
End-use Insights
The hospital segment dominated the market for diabetes-associated ophthalmic care and accounted for the largest revenue share of 39.0% in 2023. An increasing number of hospital admissions of diabetes patients is boosting the demand for the segment; patients suffering from diabetes have a threefold chance of hospitalization compared with those without diabetes, thereby propelling market growth.
Application Insights
The diabetic retinopathy segment dominated the market for diabetes associated ophthalmic and accounted for the largest revenue share of around 26.0% in 2023. Diabetic retinopathy is considered a critical medical condition that impacts the eyes of the patient leading to vision loss. According to the NCBI article (2014), around 1.5% of patients suffering from type II diabetes also have developed diabetic retinopathy, which leads to retinal neovascularization, hemorrhage, leakage of serum, and fibrovascular explosion in the vitreous retinal edge.
Hence, if ignored, it may lead to severe blindness. Furthermore, increasing clinical trials for the approval of drugs used for the treatment of diabetic retinopathy is expected to boost the growth of the market for diabetes associated ophthalmic. For instance, North America accounted for the highest number of ongoing clinical trials i.e., 397, which is immediately followed by Europe accounting for 237 clinical trials.
Regional Insights
North America dominated the diabetes-associated ophthalmic treatment market and held the largest revenue share of 37.0% in 2023. The growth in the region is mainly attributed to factors such as robust healthcare infrastructure, rising patient awareness about early disease diagnosis and treatment, supportive reimbursement policies, and the increasing prevalence of diabetes. As per CDC, about 100 million American civilians have diabetes, which is considered one of the major causes of vision loss. In addition, growing awareness regarding the availability of advanced options for treating diabetes-associated ophthalmic conditions fuels the regional market growth. Furthermore, the presence of key players such as Pfizer, Inc., and Alcon in this region is expected to further boost the growth of the market for diabetes-associated ophthalmics.
In Asia Pacific, the market for diabetes-associated ophthalmics is expected to witness the fastest growth rate during the forecast period. The growing burden of ophthalmic disorders and rising consumer awareness are expected to drive the market for diabetes-associated ophthalmology in the region. Local companies are entering into strategic initiatives to develop and commercialize new treatment options for patients. This, in turn, is expected to boost the market's growth.
Some of the prominent players in the diabetes-associated ophthalmic treatment market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global diabetes associated ophthalmic treatment market.
Application
Type
End-use
By Region
Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Application
1.1.2 Type
1.1.3 End-use
1.1.4 Regional Scope
1.1.5 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.3.5.1 Data for primary interviews in North America
1.3.5.2 Data for Primary Interviews in Europe
1.3.5.3 Data for Primary Interviews in APAC
1.3.5.4 Data for Primary Interviews in Latin America
1.3.5.5 Data for Primary Interviews in MEA
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume Price Analysis (Model 2)
1.6.2.1 Approach 2: Volume Price Analysis
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Diabetes Associated Ophthalmic Treatment Market Variables, Trends & Scope
3.1 Penetration & Growth Prospect Mapping
3.2 Market Dynamics
3.2.1 Market Drivers Analysis
3.2.1.1 Increasing prevalence of diabetes
3.2.1.2 Advancements in the technology for efficient treatment
3.2.1.3 Increasing governments initiatives
3.2.2 Market Restraint Analysis
3.2.2.1 Lack of skilled ophthalmologists
3.2.3 Market Opportunity Analysis
3.2.3.1 Increasing demand for diabetic ophthalmic diseases treatment to avoid visual impairment
3.3 Diabetes Associated Ophthalmic Treatment: Market Analysis Tools
3.3.1 SWOT Analysis by PESTEL
3.3.2 Industry Analysis-Porter’s
3.4 Impact of COVID-19
3.4.1 COVID-19 Impact analysis
3.4.2 Impact on market players
Chapter 4 Diabetes Associated Ophthalmic Treatment Market: Segment Analysis, By Application, 2024 - 2033
4.1 Definitions and Scope
4.2 Application Market Share Analysis
4.3 Segment Dashboard
4.4 Diabetes Associated Ophthalmic Treatment Market by Application
4.5 Market Size & Forecasts and Trend Analyses, 2024 to 2033 for the following
4.5.1 Dry Eye Syndrome
4.5.1.1 Dry Eye Syndrome Market Estimates and Forecast, 2021 - 2033
4.5.2 Glaucoma
4.5.2.1 Glaucoma Market Estimates and Forecast, 2021 - 2033
4.5.3 Eye Allergy & Infection
4.5.3.1 Eye Allergy & Infection Market Estimates and Forecast, 2021 - 2033
4.5.4 Diabetic Retinopathy
4.5.4.1 Diabetic Retinopathy Market Estimates and Forecast, 2021 - 2033
4.5.5 Diabetic associated Macular Degeneration
4.5.5.1 Diabetic associated Macular Degeneration Market Estimates and Forecast, 2021 - 2033
4.5.6 Uveitis
4.5.6.1 Uveitis Market Estimates and Forecast, 2021 - 2033
4.5.7 Cataract
4.5.7.1 Cataract Market Estimates and Forecast, 2021 - 2033
4.5.8 Diabetic Macular Edema
4.5.8.1 Diabetic Macular Edema Market Estimates and Forecast, 2021 - 2033
4.5.9 Others
4.5.9.1 Others Market Estimates and Forecast, 2021 - 2033
Chapter 5 Diabetes Associated Ophthalmic Treatment Market: Segment Analysis, By Type, 2024 - 2033
5.1 Definitions and Scope
5.2 Type Market Share Analysis
5.3 Segment Dashboard
5.4 Diabetes Associated Ophthalmic Treatment Market by Type
5.5 Market Size & Forecasts and Trend Analyses, 2024 to 2033 for the following
5.5.1 Drugs
5.5.1.1 Drugs Market Estimates and Forecast, 2021 - 2033
5.5.2 Devices
5.5.2.1 Devices Market Estimates and Forecast, 2021 - 2033
Chapter 6 Diabetes Associated Ophthalmic Treatment Market: Segment Analysis, By End-use, 2024 - 2033
6.1 Definitions and Scope
6.2 End-use Market Share Analysis
6.3 Segment Dashboard
6.4 Diabetes Associated Ophthalmic Treatment Market by End-use
6.5 Market Size & Forecasts and Trend Analyses, 2024 to 2033 for the following
6.5.1 Hospitals
6.5.1.1 Hospitals Market Estimates and Forecast, 2021 - 2033
6.5.2 Ophthalmic Centers
6.5.2.1 Ophthalmic Centers Market Estimates and Forecast, 2021 - 2033
6.5.3 Ambulatory Surgery Centers (ASCs)
6.5.3.1 Ambulatory Surgery Centers Market Estimates and Forecast, 2021 - 2033
6.5.4 Others
6.5.4.1 Others Market Estimates and Forecast, 2021 - 2033
Chapter 7 Diabetes Associated Ophthalmic Treatment Market: Regional Market Analysis, 2024 - 2033
7.1 Regional Market Dashboard
7.2 Definitions and Scope
7.3 Regional Market Share Analysis
7.4 North America
7.4.1 North America Market estimates and forecast, 2021 - 2033
7.4.2 U.S.
7.4.2.1 U.S. market estimates and forecast, 2021 - 2033
7.4.3 Canada
7.4.3.1 Canada market estimates and forecast, 2021 - 2033
7.5 Europe
7.5.1 Europe market estimates and forecast, 2021 - 2033
7.5.2 U.K.
7.5.2.1 U.K. market estimates and forecast, 2021 - 2033
7.5.3 Germany
7.5.3.1 Germany market estimates and forecast, 2021 - 2033
7.5.4 France
7.5.4.1 France market estimates and forecast, 2021 - 2033
7.5.5 Italy
7.5.5.1 Italy market estimates and forecast, 2021 - 2033
7.5.6 Spain
7.5.6.1 Spain market estimates and forecast, 2021 - 2033
7.6 Asia Pacific
7.6.1 Asia Pacific market estimates and forecast, 2021 - 2033
7.6.2 India
7.6.2.1 India market estimates and forecast, 2021 - 2033
7.6.3 Japan
7.6.3.1 Japan Market estimates and forecast, 2021 - 2033
7.6.4 China
7.6.4.1 China Market estimates and forecast, 2021 - 2033
7.6.5 Australia
7.6.5.1 Australia Market estimates and forecast, 2021 - 2033
7.6.6 South Korea
7.6.6.1 South Korea Market estimates and forecast, 2021 - 2033
7.7 Latin America
7.7.1 Latin America market estimates and forecast, 2021 - 2033
7.7.2 Mexico
7.7.2.1 Mexico Market estimates and forecast, 2021 - 2033
7.7.3 Brazil
7.7.3.1 Brazil market estimates and forecast, 2021 - 2033
7.7.4 Argentina
7.7.4.1 Argentina market estimates and forecast, 2021 - 2033
7.7.5 Colombia
7.7.5.1 Colombia market estimates and forecast, 2021 - 2033
7.8 Middle East and Africa
7.8.1 Middle East and Africa Market estimates and forecast, 2021 - 2033
7.8.2 South Africa
7.8.2.1 South Africa market estimates and forecast, 2021 - 2033
7.8.3 Saudi Arabia
7.8.3.1 Saudi Arabia market estimates and forecast, 2021 - 2033
7.8.4 UAE
7.8.4.1 UAE market estimates and forecast, 2021 - 2033
Chapter 8 Diabetes Associated Ophthalmic Treatment Market – Competitive Analysis
8.1 Kind of Competition
8.2 Concentration of Market Players
8.3 Company Market Share Analysis
8.4 Categorization based on the Company’s Vision
8.5 Company Profiles
8.5.1 Medtronic
8.5.1.1 Company overview
8.5.1.2 Financial performance
8.5.1.3 Product benchmarking
8.5.1.4 Strategic initiatives
8.5.2 Alcon
8.5.2.1 Company overview
8.5.2.2 Financial performance
8.5.2.3 Product benchmarking
8.5.2.4 Strategic initiatives
8.5.3 Johnson & Johnson Services, Inc.
8.5.3.1 Company overview
8.5.3.2 Financial performance
8.5.3.3 Product benchmarking
8.5.3.4 Strategic initiatives
8.5.4 Bausch Health
8.5.4.1 Company overview
8.5.4.2 Financial performance
8.5.4.3 Product benchmarking
8.5.4.4 Strategic initiatives
8.5.5 Allergan
8.5.5.1 Company overview
8.5.5.2 Financial performance
8.5.5.3 Product benchmarking
8.5.5.4 Strategic initiatives
8.5.6 Bayer AG
8.5.6.1 Company overview
8.5.6.2 Financial performance
8.5.6.3 Product benchmarking
8.5.6.4 Strategic initiatives
8.5.7 Santen Pharmaceutical Co. Ltd.
8.5.7.1 Company overview
8.5.7.2 Financial performance
8.5.7.3 Product benchmarking
8.5.7.4 Strategic initiatives
8.5.8 Novartis AG
8.5.8.1 Company overview
8.5.8.2 Financial performance
8.5.8.3 Product benchmarking
8.5.8.4 Strategic initiatives
8.5.9 Pfizer, Inc.
8.5.9.1 Company overview
8.5.9.2 Financial performance
8.5.9.3 Product benchmarking
8.5.9.4 Strategic initiatives
8.5.10 Genentech, Inc.
8.5.10.1 Company overview
8.5.10.2 Financial performance
8.5.10.3 Product benchmarking
8.5.10.4 Strategic initiatives
8.5.11 Carl Zeiss Meditec
8.5.11.1 Company overview
8.5.11.2 Financial performance
8.5.11.3 Product benchmarking
8.5.11.4 Strategic initiatives
8.5.12 Lumenis
8.5.12.1 Company overview
8.5.12.2 Financial performance
8.5.12.3 Product benchmarking
8.5.12.4 Strategic initiatives
8.5.13 Ellex Medical Lasers Ltd.
8.5.13.1 Company overview
8.5.13.2 Financial performance
8.5.13.3 Product benchmarking
8.5.13.4 Strategic initiatives
8.5.14 IRIDEX Corporation
8.5.14.1 Company overview
8.5.14.2 Financial performance
8.5.14.3 Product benchmarking
8.5.14.4 Strategic initiatives
8.5.15 Topcon Corporation
8.5.15.1 Company overview
8.5.15.2 Financial performance
8.5.15.3 Product benchmarking
8.5.15.4 Strategic initiatives
8.5.16 Abbott Medical Optics
8.5.16.1 Company overview
8.5.16.2 Financial performance
8.5.16.3 Product benchmarking
8.5.16.4 Strategic initiatives
8.5.17 Quantel
8.5.17.1 Company overview
8.5.17.2 Financial performance
8.5.17.3 Product benchmarking
8.5.17.4 Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers